Leadership

Matt Angel, Ph.D. has served as Tempest Therapeutic Inc.’s Chief Executive Officer, President and as a member of our Board since February 2026. Dr. Angel has also served as Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors of Factor Bioscience Inc. since 2011. From January 2023 to December 2023, Dr. Angel served as President and Chief Executive Officer and as a director of Ernexa Therapeutics Inc. (f/k/a Eterna Therapeutics Inc.). From May 2022 to December 2022, Dr. Angel served as Interim President, Chief Executive Officer and as a director of Ernexa Therapeutics Inc. In 2020, Dr. Angel co-founded Exacis Biotherapeutics Inc. (“Exacis”) and served as the Chief Science Officer, Secretary, Treasurer and as a director of Exacis from 2020 until the sale of Exacis in May 2023. Dr. Angel also co-founded and served as the Chief Science Officer, Secretary and as a director of Novellus, Inc., from 2014 until the sale of Novellus in July 2021. Dr. Angel received a Ph.D. from the Massachusetts Institute of Technology in 2012 and a B.S. in Engineering from Princeton University in 2003.

Stephanie Horn-Warnock has served as Tempest Therapeutic Inc.’s Chief Financial Officer since October 2026. She is a Certified Public Accountant with over 14 years of progressive experience in accounting, financial reporting, auditing, and financial management. Her professional background includes senior financial leadership roles across the healthcare, pharmaceutical, medical technology, behavioral health, and renewable energy industries, with extensive experience in U.S. GAAP compliance, internal controls, financial reporting, treasury management, and strategic financial oversight.

Since March 2026, Ms. Horn-Warnock has served in financial leadership and consulting roles through Stout Consulting, including as Controller for Diasome Pharmaceuticals, while also providing accounting and financial reporting support to Aspargo Labs and Lomond Therapeutics. In these capacities, she oversees accounting operations, financial close processes, audit coordination, and financial reporting, with a particular focus on strengthening internal controls, ensuring GAAP compliance, and supporting financial reporting requirements for pharmaceutical and clinical-stage organizations.

From January 2024 through September 2026, Ms. Horn-Warnock served as Vice President of Finance at RomTechnologies, Inc., where she led the company’s accounting and finance functions, including financial planning and analysis, budgeting, forecasting, treasury management, financial reporting, and regulatory compliance. She was responsible for establishing and enhancing internal controls, financial systems, managing complex equity reporting, and partnering with executive leadership on strategic and financial initiatives.

From 2022 to 2024, she held the positions of Senior Manager of Accounting and Assistant Controller at Palmetto Solar, where she oversaw corporate and subsidiary accounting operations, financial statement preparation, internal controls, treasury activities, and accounting teams. Previously, from 2021 to 2022, she served as Accounting Manager at Dascena, where she managed financial reporting, revenue accounting, month-end close activities, audit support, and accounting process improvements.

From 2018 to 2021, Ms. Horn-Warnock held various Controller positions at Sequel Youth and Family Services, including Divisional Controller for the Child Welfare Division, where she oversaw financial reporting, budgeting, forecasting, and accounting operations across multiple facilities. Earlier in her career, she spent six years with BDO, advancing to Assurance Manager and leading financial statement audits and reviews for publicly traded and privately held companies, including engagements involving SEC reporting requirements.

Ms. Horn-Warnock earned her Bachelor of Business Administration in Accounting from Emory University’s Goizueta Business School. She has been a Certified Public Accountant since 2018 and is a member of the American Institute of Certified Public Accountants (AICPA) and the Tennessee Society of Certified Public Accountants.

Andrew Fang, Ph.D., is a Founding Partner of YQ Advisors, where he focuses on strategic transactions and value creation in biotech and emerging technologies. He brings deep experience across cross-border licensing, asset transactions, biotech financings, and public-company strategic situations. Prior to founding YQ Advisors, Dr. Fang spent eight years at CEC Capital, where he served as Executive Director in healthcare investment banking and worked on a broad range of private placements, cross-border financings, and strategic transactions for biotechnology companies. His transaction experience includes work with innovative and late-stage clinical-stage companies such as iRegene, Connect Biopharma, Everest Medicines, Haihe Biopharma, Arctic Vision, and other public and venture-backed biopharma companies. At YQ Advisors, he focuses on ex-China/global licensing, M&A and reverse merger opportunities involving public biotech companies, and the incubation of early-stage biotech platforms, particularly in cell and gene therapy and AI-enabled biotech. Dr. Fang holds a Ph.D. in Chemical & Chemical Biology from Rutgers University and a bachelor’s degree in Materials Science from the University of Science and Technology of China.